Search results
Results from the WOW.Com Content Network
SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. [2] Positive results of Phase I trials for the vaccine were published in The Lancet [3] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. [4]
Pharmaceutical compound S-268019 Vaccine description Target SARS-CoV-2 Vaccine type Protein subunit Clinical data Routes of administration Intramuscular Identifiers CAS Number 2696247-53-5 Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline ...
Vaccine Excipients Adenovirus vaccine: This list refers to the type 4 and type 7 adenovirus vaccine tablets licensed in the US: Acetone, alcohol, anhydrous lactose, castor oil, cellulose acetate phthalate, dextrose, D-fructose, D-mannose, FD&C Yellow #6 aluminium lake dye, fetal bovine serum, human serum albumin, magnesium stearate, micro crystalline cellulose, plasdone C, Polacrilin potassium ...
Accordingly, all dossiers and data presenting information about the search for the only made-in-Vietnam COVID-19 vaccine have been submitted to the MoH's Advisory Council for the Registration of Circulation of Drugs and Medicinal Ingredients for emergency use authorization.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe. [8] [11] It was proposed specifically for production of COVID-19 vaccines. [12] [13] In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old. [3] The authorization ...
In April, Ad5-nCoV became the first COVID-19 vaccine candidate in the world to begin Phase II trials. [30] The Phase II trial results were published in the peer-reviewed journal The Lancet in August 2020, and noted neutralizing antibody and T cell responses based on statistical analyses of data involving 508 eligible participants. [31]
Pharmaceutical compound Sinopharm CNBG COVID-19 vaccine Vaccine description Target SARS-CoV-2 Vaccine type Protein subunit Clinical data Routes of administration Intramuscular Legal status Legal status Full list of Sinopharm NVSI authorizations Identifiers CAS Number 2503126-65-4 Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS ...